key: cord-0279553-xeqlwu01
authors: Parvez, Md Sorwer Alam; Saha, Manash Kumar; Ibrahim, Md.; Araf, Yusha; Islam, Md. Taufiqul; Ohtsuki, Gen; Hosen, Mohammad Jakir
title: Insights from a computational analysis of the SARS-CoV-2 Omicron variant: Host-pathogen interaction, pathogenicity and possible therapeutics
date: 2022-01-20
journal: nan
DOI: 10.1002/iid3.639
sha: 68aab5e4977fd0632978fcbe4c43f405e68e511d
doc_id: 279553
cord_uid: xeqlwu01

Prominently accountable for the upsurge of COVID-19 cases as the world attempts to recover from the previous two waves, Omicron has further threatened the conventional therapeutic approaches. Omicron is the fifth variant of concern (VOC), which comprises more than 10 mutations in the receptor-binding domain (RBD) of the spike protein. However, the lack of extensive research regarding Omicron has raised the need to establish correlations to understand this variant by structural comparisons. Here, we evaluate, correlate, and compare its genomic sequences through an immunoinformatic approach with wild and mutant RBD forms of the spike protein to understand its epidemiological characteristics and responses towards existing drugs for better patient management. Our computational analyses provided insights into infectious and pathogenic trails of the Omicron variant. In addition, while the analysis represented South Africa's Omicron variant being similar to the highly-infectious B.1.620 variant, mutations within the prominent proteins are hypothesized to alter its pathogenicity. Moreover, docking evaluations revealed significant differences in binding affinity with human receptors, ACE2 and NRP1. Owing to its characteristics of rendering existing treatments ineffective, we evaluated the drug efficacy against their target protein encoded in the Omicron through molecular docking approach. Most of the tested drugs were proven to be effective. Nirmatrelvir (Paxlovid), MPro 13b, and Lopinavir displayed increased effectiveness and efficacy, while Ivermectin showed the best result against Omicron.

Introduction COVID-19 pandemic by the SARS-CoV-2 (also known as coronavirus) has pulverized the health care system of the world since November 2019, which changed our lives and caused strict measures to prevent the spread of infection (WHO, 2021, October 13) . Currently, most countries are threatened by the 3 rd to 6 th wave of this severe acute respiratory disease, and the entire world is trying to combat it (Hiscott et al., 2020) . It's a situation constantly changing and evolving (Anwar et al., 2020) . Multiple forms of this virus, including alpha, beta, gamma, and delta have shown its rampage, and most recently, the omicron form is circulating over the world with a hot spot of more than 30 mutations in the spike protein WHO, 2021, November 26 ).

Omicron, a newly evolved and very highly-infectious coronavirus variant (B.1.1.529), was designated as a variant of serious concern by the World Health Organization on November 26, 2021 (Collie et al., 2021) . Since the first case report in Botswana on November 11, 2021, Omicron has spread to 108 countries and infected 150-thousand patients within a month, despite greater surveillance. While it is too early to assess exact severity, preliminary findings suggest that Omicron has a less clinical presentation and 4.9% lower hospital admission rates (Jassat et al., 2021) . It is the most highly-altered version, similar to those reported in earlier variants of concern, linked to its increased transmissibility and partial resistance to vaccine-induced immunity (Collie et al., 2021; Torjesen, 2021; Gu et al., 2021) . Omicron was born into a COVID-19-weary world and repleted with further anxiety and distrust at the pandemic's extensive detrimental social, emotional, and economic consequences The laboratories chasing the Omicron variant have yet thoroughly defined its epidemiologic characteristics. The features of DNA sequence alone cannot be used to determine them, which causes a diagnostic challenge. Concerning the spike protein of the Omicron variant, mutations were reported in the S protein. The alterations in the S protein receptor-binding domain (RBD) may influence its infectivity and antibody resistance, as RBD is necessary for binding with host angiotensin-converting enzyme 2 (ACE2) during the early infection process. The binding free energy (BFE) between the S RBD and the ACE2 has been demonstrated proportional to viral infectivity in several investigations. Moreover, mutations in the nucleocapsid protein have also been reported in Omicron, which helps viral proliferation (Gu et al., 2021) . Increased transmissibility, better viral binding affinity, and higher antibody escape would have all been linked to these mutations .

The Omicron variant has currently become a great concern for the world. Basic research is required to unveil its molecular consequences via gene mutations, which resulted in changes in infectivity, pathogenicity, and antigenic escape potential (Harvey et al., 2021) . Both occurrence area and the variant of Omicron origin are also unclear. To face the challenge of Omicron, it is urgent to test possible therapeutics and the effectiveness of available vaccines. Therefore, our study aimed to elucidate the novelty of Omicron from other variants: molecular mechanism of its high infectious ability and less pathogenicity. We also analyzed the effectiveness of current promising drugs against this variant. Our findings should provide novel insights on the structural and functional impact of mutations in Omicron, the impact during host interaction, and possible therapeutics for combatting this highly infectious variant.

Retrieval of the Sequences:

The complete genome sequences of all notable SARS-CoV-2 variants including the variant of concern (VOC) and the variant of interest (VOI) were retrieved from the GISAID database (www.gisaid.org). We collected a total number of 30 variants along with South Africa variant B.1.1.529 (Omicron) from this database. Additionally, the sequence of the Wuhan SARS-CoV-2 was also retrieved and considered as the reference for the comparative analysis.

We performed multiple sequence alignment (MSA) using MUSCLE alignment tools (Edgar, 2004) . Further, we used this MSA file for the reconstruction of a phylogenetic tree. IQ-TREE was adopted for the reconstruction of the tree with Maximum Likelihood (ML) method (Nguyen et al., 2015) . To identify the best-fit substitution model, we used ModelFinder for the model test (279 models) and selected the best-fit substitution model (GTR+F+R2) based on Bayesian Information Criterion (BIC) which is a criterion for model selection and generally model with lower BIC is considered as good (Kalyaanamoorthy et al., 2017) . BIC is calculated with the following equations:

Here, k= number of parameters estimated by the model N= the number of data points in the number of observations or equivalently, the sample size L= the maximized value of the likelihood function of the model Besides, we performed both SH-aLRT and ultrafast bootstrap to assess branch supports where both were set to 1000. UFBoot2 was used for this bootstraps assessment operation (Hoang et al., 2018) .

Finally, we employed an iTOL online tool for the visualization and analysis of the reconstructed phylogenetic tree (Letunic and Bork, 2021) .

The MSA file was analyzed by MEGAX software to identify the nucleotide variations in all variants, considering the Wuhan strain as a reference (Kumar et al., 2018) .

To predict the genes and their encoded proteins in the variant genome, we used FGENESV (uses pattern recognition and Markov chain models) of Softberry (http://linux1.softberry.com/berry.phtml) viral gene prediction tools. The predicted genes and proteins were further confirmed using the Basic Local Alignment Search Tool (BLAST) of NCBI (https://blast.ncbi.nlm.nih.gov/Blast.cgi). A pair-wise alignment of each protein with its corresponding protein of the reference strain was further performed to identify the amino acid variations in each protein by adopting Clustal omega, and visualized and analyzed in MVIEW (Sievers and Higgins, 2014; Brown et al., 1998) .

The 3D crystal structure of wild RBD of spike protein was retrieved from the Protein Data Bank database (https://www.rcsb.org/) with the accession number of PDB ID: 6M17 (Berman et al., 2000) . This structure was cleaned by removing water, ligand, and other complexed molecules using the PyMOL (DeLano, 2002) . We modeled the 3D structure of mutant RBD of Omicron variant using SWISS-MODEL (https://swissmodel.expasy.org/) web server (Kiefer et al., 2009 ).

Then, the generated 3D structure was validated by using ERRAT and PROCHECK (Colovos and Yeates, 1993; Laskowski et al., 1993) .

We analyzed the interaction of both wild and mutant RBD of spike protein with human receptors ACE2, NRP-1, BSG, and DPP4 through protein-protein molecular docking using FRODOCK tools (Ramírez-Aportela et al., 2016) . We selected these four human receptors, as previous studies demonstrated that spike protein interacts with them. The 3D structure of the receptor proteins was retrieved from the PDB except for NRP-1. Due to the unavailability of NRP-1 3D structure in PDB, we retrieved it from the Alphafold database (Jumper et al., 2021) . Then, we prepared the input PDB file by converting it to PQR format using PDB2PQR, which is a Python-based structural conversion utility (Dolinsky et al., 2004) . We used CHARMM force field during the proteinprotein docking simulation (Vanommeslaeghe et al., 2010) . Finally, we calculated and obtained the binding energy of the binding interaction by using the PISA server (https://www.ebi.ac.uk/msd-srv/prot_int/cgi-bin/piserver).

We analyzed ten promising drugs targeting the main (3CL) protease protein of SARS-CoV-2

including Nirmatrelvir, Ritonvir, Ivermectin, Lopinavir, Boceprevir, MPro 13b, MPro N3, GC-373, GC376, and PF-00835231 (Jin et al., 2020; Zhang et al., 2020; Vandyck and Deval, 2021) .

The PDB structures of these drugs were retrieved from the DrugBank (https://go.drugbank.com/)

and PubChem (https://pubchem.ncbi.nlm.nih.gov/) (Wishart et al., 2018; Kim et al., 2016) . The 3D structure of the wild main protease was retrieved from PDB ID: 6WTK. We modeled the mutant by SWISS-MODEL (Kiefer et al., 2009 ). Prior to the molecular docking, we removed water molecules, ligands, and other complex molecules from the 3D structures. Polar hydrogen atoms and required charges for the energy minimization were further added. Molecular docking was performed by using AutoDock Vina tools (Trott and Olson, 2010) . We set parameters of the grid box to size 40 Å × 64 Å × 64 Å (x, y, and z) and center -16.773 × -15.229 × 13.709 (x, y, and z). Further, we used PyMOL for the analysis and visualization of the protein-ligand complex molecules (DeLano, 2002) . The 2D diagrams of Protein-ligand interaction were generated with Discovery Studio (Biovia, 2017) .

Phylogenetic Analysis:

First, we reconstructed a phylogenetic tree from the multiple sequence alignment of all notable variants, including South Africa B.1.1.529 (Omicron) . We further reconstructed an un-rooted phylogenetic tree through maximum likelihood (ML) methods to find closely related variants.

Surprisingly, we found that the Omicron variant was very closely related to SARS-CoV-2 variants of Germany B.1.620 (Fig 1) . Interestingly, the Switzerland B.1.1.318 variant was also localized close to the Omicron variant. All variants were centered at the Wuhan strain (Fig 1, red circle) which was the very early strain of SARS-CoV-2.

Variations in the genome sequences of all notable variants from the alignment file were identified by comparing them with the Wuhan strain. We found that the variant South Africa B. Omicron contained the maximum number of non-synonymous mutations (50 non-synonymous mutations). Remarkably, we found most of these non-synonymous mutations to locate in the spike protein sequence. Importantly, some of the deletion and insertion was found in the consecutive bases of Omicron affect encoded proteins ( Table 2) .

FGENESV and further pairwise alignment analysis demonstrated that the Omicron variant had mutations across polyprotein ab, spike protein, envelope protein, membrane glycoprotein, and nucleocapsid phosphoprotein (Table 3 ). Most numbers of the mutations were found located in spike protein. In the case of polyprotein ab, mutations occurred in papain-like protease nsp3, nsp4, 3C like protease nsp5, nsp6, RNA dependent RNA polymerase nsp12, and proofreading exoribonuclease nsp14. Interestingly, deletions of three consecutive amino acids at positions 31 to 33 were detected in nucleocapsid phosphoprotein.

The 3D modeling of mutant RBD of spike protein was done by SWISS-MODEL homology modeling using wild-type RBD of spike protein (with PDB ID 6M17) as a template. We further validated the obtained 3D model through ERRAT and PROCHECK tools. ERRAT validation revealed the overall quality factor of this model was 97.5 (Fig 2) . Ramachandran plot analysis by PROCHECK revealed that 91.8% of its residues were in the most favoured regions, and 7.6% were in additional allowed regions (Fig 2) . A model would be considered as a good quality and highreliability if it has over 90% of its residues in the most favoured regions. All these validation scores suggested that this model was highly reliable to use for further analysis.

Next, we performed molecular docking analysis to investigate the impact of mutations in the RBD spike protein in interaction with human receptors. We used four previously reported receptors, including ACE2, NRP-1, DPP4, and BSG in this analysis (Scialo et al., 2020; Daly et al., 2020; Yang et al., 2021; Essahib et al., 2020) . Docking analysis revealed that the binding energy for interaction with ACE2 was decreased from -15.9 to -17.2 while increased for NRP1 from -27.2 to -22.9, compared to wild-type RBD (Table 4 & Fig 3) . The other two receptors showed higher binding energy in both wild and mutant type RBD, compared to ACE2 and NRP1.

Nirmatrelvir, Ritonvir, Ivermectin, Lopinavir, Boceprevir, MPro 13b, MPro N3, GC-373, GC376, and PF-00835231 were reported as effective against SARS-CoV-2, and most of them were currently in the clinical trials. To investigate the effectiveness of these drugs, we performed molecular docking against the main protease protein of Omicron. We found that mutations in the main protease that occurred in the Omicron variant didn't significantly affect the binding energy for the interaction between these drugs and the main protease (Table 5 ). The binding affinity increased for Nirmatrelvir, MPro 13b, and Lopinavir (Fig 4) , whereas no changes for Ivermectin, MPro N3, and GC-373. The lowest binding energy was found for Ivermectin against both wild and mutant main protease. The binding site for all drugs was similar, however, the interacted amino acids were different (Fig 5) .

Twenty-three months following the first emerging cases of COVID-19 alongside its several variant classifications, another VOC, known as Omicron or B. (Poudel et al., 2022) . The spike protein or S protein of Omicron is known to be the major site of mutation, which is also labeled to have increased infectivity and transmissibility owing to its protein-specific mutations. A similar mutation trend followed by previous VOCs, alongside other changes within the viral genome, also raises concerns associated with antiviral drug effectiveness, antibody therapies, and vaccineconferred immunity (Kannan et al., 2022; Hoffmann et al., 2021) . Upholding these concerns, the Omicron variant has reportedly not only rendered vaccines less effective but has also contributed to compromising antibody-based therapies, which have been proving to be the conventional lifesavers. Consequently, the need for novel effective antivirals and an evaluation of their targeted action against the virus remains of crucial significance. Through comprehensive evaluations, our study identified the structure-based indifferences of the now emerging and dominant variant,

Omicron. Further, this study elucidated not only the associated interactions between the RBD of spike protein and human receptors but also the effectiveness of the existing antiviral drugs.

Our extensive evaluations into the phylogenetic tree analysis initially indicated that the into several non-structural proteins. We also found mutations in these proteins, including papainlike protease nsp3, nsp4, 3CL protease nsp5, nsp6, RNA dependent RNA polymerase nsp12, and proofreading exoribonuclease nsp14. Seemingly, a study by Zhu et al. (2021) observed through Drosophila viability assays that nsp6 was one of the most pathogenic SARS-CoV-2 genes, capable of triggering lethal consequences individually and, at the same time, was labeled as one of the primary determinants of COVID-19 pathogenesis (Zhu et al., 2021) . Mutations in this protein could affect the intracellular survival of the virus and could also make a significant modification in viral pathogenicity (Benvenuto et al., 2020) . Three consecutive deletions and a substitution mutation in the genome sequence of Omicron possibly indicate a reduced pathogenicity. Mutations of nsp3, a major protein for the SARS-CoV-2 replication, suggest a lower replication rate and infectivity. These two proteins, along with nsp4 and nsp5, are known for double-membraned vesicle (DMV) inductions and localizations of cleaved maps (Gorkhali et al., 2021; Angelini et al., 2013) . While nsp12 and nsp14, which are required to mediate polymerase and exonuclease activities, had also been shown genetic alterations presumably affecting their viral load, other structural proteins were also mutated. These include the Spike (S) protein which is responsible for facilitating the membrane fusion and viral entry (Tortorici and Veesler, 2019) ; the Envelope (E) protein which is contributory to virus morphogenesis and pathogenesis (Hogue and Machamer, 2014) ; the Membrane (M) protein which aids membrane fusion through its initial attachment to the S protein and surface receptors of the host (Lai and Cavanagh, 1997; Fleming et al., 1989) ; the Nucleocapsid (N) protein moderates replication and viral RNA synthesis, transcription and metabolism associated with infected cells and additionally provides stability to the RNA inside the cell (Cong et al., 2019; Huang et al., 2004; Nelson et al., 2000; Stohlman et al., 1988) . While these generalized protein roles and their mutations may help hypothesize Omicron as less pathogenic than others, only further research into their gene-specific mutations of the Omicron variant may act as better pointers for characteristic identification.

With a maximum of mutations in the spike (S) protein, the mutant RBD of that very protein was modeled and validated for further analysis. We studied the chosen human receptors, including ACE2, NRP1, DPP4, and BSG, through molecular docking processes to understand their interactions with the mutant RBD of the spike protein. Notably, the results indicated a decreased binding energy for interacting mutant RBD with ACE2 and a significantly increased binding energy for interacting mutant RBD with NRP1, compared to the wild-type RBD. However, both DPP4 and BSG showed higher binding energies in either form, compared to the former two human receptors. Spike protein RBD of the Omicron variant contains 11 mutations, and they may be the responsible elements for increasing binding affinity for the interaction with ACE2. Mutations in RBD occurred for an optimization of the binding affinity, which would be advantageous for the virus to enhance its transmissibility. Barton et al. reported that three mutations of RBD: N501Y, E484K, and S477N enhance the binding affinity for interaction with ACE2 ( Barton et al., 2021) .

Surprisingly, all these mutations were available in the spike protein RBD of the Omicron variant, and they may be responsible for increased binding affinity. Acknowledging the characteristic label of infecting 70 times faster than the deadly Delta variant and the initial COVID-19 strain but likely being less severe (Luo et al., 2021) , a generalized hypothesis may be provided alongside the results of our study. Owing to its greater infectivity but lower pathogenicity, as a comparison to its receptor binding capacity, it may be hypothesized that ACE2 is responsible for increased infectivity whereas NRP1 is associated with increased pathogenicity. Therefore, in cases of the Omicron variant, the increased binding affinity for ACE2 corresponds to its greater infection rate whereas, decreased binding affinity for NRP1 may correspond to a decreased pathogenicity. However, Ivermectin showed the highest binding affinity and may be the most effective drug candidate against the Omicron variant. While these hypotheses hold great value and may provide significant insights into the therapeutic strategies, further research is crucial to authenticate these statements.

The world is now afraid of the highly infectious omicron variant, and research is required to know about this variant. Our study gave an insight into its probable molecular consequences about infectivity and pathogenicity of the Omicron variant. The study also demonstrated that the highly infectious B.1.620 strain may be the origin of the Omicron variant, and mutations in all major proteins made omicron less pathogenic. Through docking analysis, we revealed that the mutations in spike protein increased its binding affinity for its main receptor ACE2 while decreased binding affinity for its co-receptor NRP-1. All the promising drugs that target the main protease would also be effective against this variant; however, Ivermectin shows the strongest binding affinity, and Nirmatrelvir (Paxlovid), MPro 13b, and Lopinavir may be more effective against this variant.

This work was supported by grants from the Mitsubishi Foundation, the Takeda Science Foundation (to G.O.).

The authors have declared no competing interest. Table 3 : Mutations in the proteins encoded by omicron variant 5 Table 4 : Binding energy of interaction between wild-type and mutant RBD with human receptors 6 Here, green color represents ACE2, yellow color for wild type RBD and red color for mutant RBD. B, Interaction of RBD with NRP1. Here, blue color represents NRP1, yellow color for wild type RBD, and red color for mutant RBD.

Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles

COVID-19 and Bangladesh: challenges and how to address them

Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics

Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy

The protein data bank

Discovery studio modeling environment

MView: a web-compatible database search or multiple alignment viewer

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

Verification of protein structures: patterns of nonbonded atomic interactions

Nucleocapsid protein recruitment to replication-transcription complexes plays a crucial role in coronaviral life cycle

Neuropilin-1 is a host factor for SARS-CoV-2 infection

The PyMOL: Molecular Graphics System

PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations

Emergence and spread of SARS-CoV-2 lineage B. 1.620 with variant of concern-like mutations and deletions

MUSCLE: multiple sequence alignment with high accuracy and high throughput

SARS-CoV-2 host receptors ACE2 and CD147 (BSG) are present on human oocytes and blastocysts

Monoclonal antibodies to the matrix (El) glycoprotein of mouse hepatitis virus protect mice from encephalitis

Structure and Function of Major SARS-CoV-2 and SARS-CoV Proteins

SARS-CoV-2 variants, spike mutations and immune escape

The Omicron variant is highly resistant against antibody-mediated neutralizationimplications for control of the COVID-19 pandemic

The global impact of the coronavirus pandemic

UFBoot2: improving the ultrafast bootstrap approximation

Coronavirus structural proteins and virus assembly. Nidoviruses

Structure of the N-terminal RNA-binding domain of the SARS CoV nucleocapsid protein

Clinical Severity of COVID-19 Patients Admitted to Hospitals in Gauteng, South Africa During the Omicron-Dominant Fourth Wave

Structure of M pro from SARS-CoV-2 and discovery of its inhibitors

Highly accurate protein structure prediction with AlphaFold

ModelFinder: fast model selection for accurate phylogenetic estimates

Appropriate names for COVID-19 variants

Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses

CoV-2 variant: Unique features and their impact on pre-existing antibodies

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic

The SWISS-MODEL Repository and associated resources

PubChem substance and compound databases

MEGA X: molecular evolutionary genetics analysis across computing platforms

The molecular biology of coronaviruses

PROCHECK: a program to check the stereochemical quality of protein structures

Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree display and annotation

From SARS to the Omicron variant of COVID-19: China's policy adjustments and changes to prevent and control infectious diseases

High affinity interaction between nucleocapsid protein and leader/intergenic sequence of mouse hepatitis virus RNA

IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies

Highly mutated SARS-CoV-2 Omicron variant sparks significant concern among global experts-What is known so far

FRODOCK 2.0: fast proteinprotein docking server

ACE2: the major cell entry receptor for SARS-CoV-2. Lung

Clustal omega

Specific interaction between coronavirus leader RNA and nucleocapsid protein

Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear

Structural insights into coronavirus entry

AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields

Considerations for the Discovery and Development of 3-Chymotrypsin-Like Cysteine Protease Inhibitors Targeting SARS-CoV-2 Infection. Current Opinion in Virology

DrugBank 5.0: a major update to the DrugBank database

Impact of COVID-19 on people's livelihoods, their health and our food systems

World Health Organization (WHO)

DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis

Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Functional analysis of SARS-CoV-2 proteins in Drosophila identifies Orf6-induced pathogenic effects with Selinexor as an effective treatment